The clinical trial focused on very young children, who have a more rapid loss of the pancreatic beta cells than do adolescents. The trial was constrained to a low-dose level, but showed safety and tolerability and reduced serum glucagon, a secondary outcome.

Type 2 diabetes is alarmingly on the rise in Alabama youth, but following a healthy diet and exercising regularly can help mitigate the risk and the severity.

Published results suggest the COVID-19 pandemic exacerbated the slow increase in pediatric Type 2 diabetes.

Record $95 million Heersink lead gift to advance strategic growth and biomedical innovation.